Abstracts

HIV DNA Peripheral Reservoirs Have a Nonlinear Impact on Brain Pathology

Background: The HIV reservoir in peripheral blood mononuclear cells (PBMC) contributes to HIV-associated dementia (HAD) pathogenesis. However it is unclear whether it contributes to non-demented HIV-associated neurocognitive disorders (HAND) that are more common in chronic HIV infection (CHI), especially in HIV+ persons on long-term combined antiretroviral therapy (cART). Methods: Eighty adults (mean age=55, 1 female)…

Acute HIV CSF/Plasma RNA Ratios Are Variable and Greater Than in Chronic HIV

Background: Clarifying the early dynamics of HIV invasion into the central nervous system (CNS) will inform understanding of the neurologic complications of HIV, and may facilitate cure interventions that rely on preventing establishment of viral reservoirs. Methods: Forty-two Thai subjects identified in the acute phase of HIV infection (Fiebig I-V) had plasma and cerebrospinal fluid…

Greater CSF HIV Reduction and CSF Rapid Decay Associated with Improved Neurocognition

Background: HIV Associated Neurocognitive impairment remains problematic despite suppressive antiretroviral therapy (ART). Underlying low level HIV infection likely persists in the central nervous system (CNS) and may sustain inflammation causing neuronal damage. We sought to better understand the dynamics of HIV in the cerebrospinal fluid (CSF) during treatment initiation and the relationship to neurocognitive outcomes.…

HIV-1 Replication in the CNS Is Associated With Increased Neurocognitive Impairment

Background: HIV-infected individuals are reported to have higher levels of neurocognitive impairment than HIV-negative controls. We examined the association between independent HIV-1 replication in the CNS and neurocognitive impairment. Methods: We used cerebrospinal fluid (CSF) and blood plasma samples from 40 subjects off antiretroviral therapy (ART) to characterize viral populations in the CNS and blood.…

Maraviroc-Enhanced CART Improves Cognition in Virally Suppressed HAND: A Pilot Study

Background: HIV-associated neurocognitive disorders (HAND) occur despite viral suppression in blood and cerebrospinal fluid on combined antiretroviral therapy (CART). One therapeutic option may be CART enhancement with Maraviroc (MA) as MA can penetrate the Central Nervous System (CNS) and has dual antiretroviral/anti-inflammatory activity. Methods: 19 virally-suppressed HIV+ males (M=53 years old) with formally diagnosed HAND…

Similar Neurocognitive Performance in Patients on ATV/r Monotherapy vs Triple Therapy

Background: To assess efficacy in Central Nervous System (CNS), we evaluated neurocognitive performance in patients (pts) on atazanavir/ritonavir (ATV/r) monotherapy compared to ATV/r triple therapy. Methods: MODAt (NCT01511809) is a multicentric, randomized, open-label, non-inferiority trial. Pts on ATV/r 300/100mg+2 N(t)RTIs since≥48 weeks, virologically suppressed since≥24 weeks, were randomized to ATV/r (arm A) or to maintain…

Cerebrospinal Fluid Markers in Long-Term Atazanavir/Ritonavir Monotherapy

Background: Central nervous system (CNS) viral escape is a concern in ritonavir boosted protease inhibitors monotherapy. Aim was to assess viral escape and immuneactivation marker levels in the cerebrospinal fluid (CSF) of patients on successful long-term atazanavir/ritonavir (ATV/r) monotherapy. Methods: MODAt (NCT01511809) is a multicentric, randomized, open-label, non-inferiority trial. Patients on ATV/r 300/100mg+2 N(t)RTIs since≥48…

Neurocognitive Decline Is Associated With Antiretroviral Concentrations in Plasma and Cerebrospinal Fluid (CSF)

Background: Therapeutic antiretroviral therapy (ART) drug concentrations in the central nervous system (CNS) are likely important for controlling HIV replication in the brain although their relationship to neurocognitive impairment (NCI) remains controversial. The objective was to investigate associations between drug concentrations with incident NCI in a randomized clinical trial comparing two ART regimens, tenofovir-lamivudine-efavirenz (TDF-3TC-EFV,…

Rates of Nonconfounded HIV-Associated Neurocognitive Disorder After Early cART

Background: HIV-Associated Neurocognitive Disorder (HAND) is an important complication of chronic HIV-infection with an estimated prevalence ranging from 19 – 45%. We investigated the prevalence of non-confounded HAND in an HIV positive cohort who previously initiated long-term cART with a median duration of infection of 1.6 months. Methods: Participants were randomly selected from the ADARC…